A pilot study conducted with oocyte donors and a GnRH antagonist protocol evaluated the possibility of preventing OHSS by increasing the daily GnRH antagonist dose (twice per day) before ovulation triggering (hCG) in patients at risk of OHSS (63). The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.